AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03426345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily for 12 weeks.
Study NCT01149941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study NCT01149941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study NCT03534024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nanomicielle curcumin
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study NCT03534024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study NCT03265561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone allograft
Description: All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
Study NCT03265561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone auto and allograft group
Description: All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
Study NCT01448733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Description: Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
Study NCT02865161 — intervention group
Intervention type: DRUG
Intervention: NISELAT
Description: NISELAT 600MG BD
Study NCT03277131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DURAFIBER Ag
Description: DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
Study NCT01802151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
Study NCT04559321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.
Description: General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
Study NCT04559321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.
Description: General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
Study NCT00107887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH preventive therapy
Description: Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
Study NCT00244439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG
Description: 30 minute application
Study NCT00244439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovide (malathion) lotion 0.05%
Description: 8-12 hour application
Study NCT00244439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1%
Description: 10 minute application
Study NCT03164642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA with Feedback
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
Study NCT03164642 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LENA no feedback
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
Study NCT02736617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02736617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT00193453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 30min IV, Day 1 \& 8
Study NCT00193453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30mg/m2, 30min IV, day 1 \& 8
Study NCT00193453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
Study NCT01533259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognition
Description: Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic Nervous System
Description: The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sympathetic Nervous System
Description: The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Concentratio and Attention
Description: Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
Study NCT04560881 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine
Description: Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
Study NCT00107887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST (tuberculin skin test)
Description: Clinics will be trained in the use of TST for assessing exposure to TB
Study NCT04272229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Concentratio and Attention
Description: Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
Study NCT00819039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant administered orally or intraveously.
Study NCT00819039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron administered intravenously.
Study NCT03045172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP
Study NCT03045172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT03366246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine / Prilocaine Cream
Description: according randomized this side received placebo or active product
Study NCT03366246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: according randomized this side received placebo or active product
Study NCT03693196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PICF, Perio-paper®
Description: PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
Study NCT03693196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subgingival Plaque, Hu-Friedy®
Description: Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
Study NCT03693196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Williams probe, PCPNU-15 Hu-Friedy®
Description: Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
Study NCT03693196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Demographic
Description: Age, gender and state of smoking were compared between groups.
Study NCT03694704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FineHearing strategy
Description: Cochlear implant with FineHearing strategy
Study NCT03442452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Decision Aid Tool
Description: The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
Study NCT00909844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (I.N.N.)
Description: Decapeptyl® SR 11.25mg
Study NCT03217409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Ezetimibe
Description: Rosuvastatin 5mg+Ezetimibe 10mg
Study NCT03217409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5Mg Tablet
Study NCT00694772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery-tonsillectomy
Description: standard of care electrocautery tonsillectomy
Study NCT00694772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coblation-tonsillotomy
Description: use of Arthrocare Coblation Technology to perform tonsillotomy
Study NCT02605330 — intervention group
Intervention type: PROCEDURE
Intervention: Fibrinogen plasma level
Description: At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Study NCT03581006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Low-Calorie Mediterranean Diet
Description: Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
Study NCT03581006 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Technology based monitoring and behavioral participation
Description: Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
Study NCT03581006 — intervention group
Intervention type: OTHER
Intervention: Usual care group
Description: Control group, who will receive no dietary or behavioral intervention during the trial
Study NCT04653311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina®
Description: Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
Study NCT03807635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergoLance safety lancet
Description: The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
Study NCT03807635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance safety lancet
Description: The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
Study NCT00601055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving-Rx Adherence (PSA)
Description: In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
Study NCT00601055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PID-C
Description: In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
Study NCT03413514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACT
Description: SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)
Study NCT03413514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDM
Description: Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
Study NCT03413514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery with D2 lymph node dissection
Study NCT03413514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT
Description: SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)
Study NCT03413514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
Study NCT04324749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted peanuts (group A)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
Study NCT04324749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut butter (group B)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
Study NCT04324749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (group C)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
Study NCT01925443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Will be performed irradiation with low-intensity laser in quadriceps muscle
Study NCT00605683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
Study NCT00605683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Study NCT00605683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Study NCT02936947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Percussive Ventilation
Description: High Frequency Percussive Ventilation
Study NCT02936947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free breathing
Description: Free breathing
Study NCT02936947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Breathing Control
Description: Active Breathing Control
Study NCT02964624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.